You are here:
NZLII >>
Databases >>
New Zealand Bill of Rights Act Reports >>
2022 >>
[2022] NZBORARp 71
Database Search
| Name Search
| Recent Documents
| Noteup
| LawCite
| Download
| Help
Therapeutic Products Bill (Consistent) (Sections 14, 20, 21, 25(c) and 26(2)) [2022] NZBORARp 71 (21 November 2022)
Last Updated: 11 December 2022
21 November 2022
LEGAL ADVICE
LPA 01 01 24
Hon David Parker, Attorney-General
Consistency with the New Zealand Bill of Rights Act 1990: Therapeutic Products
Bill
Purpose
- We
have considered whether the Therapeutic Products Bill (the Bill) is consistent
with the rights and freedoms affirmed in the New
Zealand Bill of Rights Act 1990
(the Bill of Rights Act).
- We
have not yet received a final version of the Bill. This advice has been prepared
in relation to the latest version of the Bill
(PCO 19563/45.2) received on 18
November 2022. We will provide you with further advice if the final version
includes amendments that
affect the conclusions in this
advice.
Summary
- The
Bill is intended to replace the current Medicines Act 1981 and Dietary
Supplements Regulations 1985 to provide for the comprehensive,
risk-proportionate regulation of therapeutic products.
- Therapeutic
products are medicines, medical devices, Natural Health Products
(NHPs)1, and active pharmaceutical ingredients (APIS).
They include:
- Medicines
made from biological components, gene therapies, and advanced cell and tissue
therapies;
- Medical
devices that are software, production systems, whole organs and tissue grafts;
and
- NHPs
that are traditional and herbal medicines, and vitamin and mineral
supplements.
- Therapeutic
products are used by all New Zealanders in their everyday lives and in all parts
of the health system.
- We
have concluded that the Bill appears to be consistent with the rights and
freedoms affirmed in the Bill of Rights Act. In reaching
that conclusion, we
have considered the consistency of the Bill with:
- section
14 (freedom of expression);
1 NHPs are traditional and
herbal medicines, and vitamin and mineral supplements. Examples include
rongoā Māori (traditional
Māori remedies) and traditional Chinese
medicine, as well as low concentration NHPs.
- section
20 (rights of minorities);
- section
21 (unreasonable search and seizure);
- section
25(c) (the right to be presumed innocent until proven guilty); and
- section
26(2) (double jeopardy).
- Our
analysis is set out below.
The Bill
- The
purpose of the Bill is to protect, promote, and improve the health of all New
Zealanders by providing for the —
- acceptable
safety, quality, and efficacy of medicines and APIs across their life cycle;
and
- acceptable
safety, quality, and performance of medical devices across their life cycle;
and
- acceptable
safety and quality of NHPs across their life cycle.
- A
therapeutic product is one that is intended to be used by humans for a
therapeutic purpose. This includes: preventing, diagnosing,
monitoring,
alleviating, treating, curing, or compensating for a disease, ailment, defect,
or injury; testing the susceptibility
of humans to a disease or an ailment;
investigating, replacing, modifying, or supporting part of a human’s
anatomy; disinfecting
medical devices; and maintaining health and providing for
human nutritional supplementation.
- While
therapeutic products can provide enormous benefits, they are not risk-free. The
ingredients used in a product may be inherently
risky (for example, many
chemotherapies), harmful in large amounts (for example, many pain relievers) or
present unique risks to
different groups (for example, pregnant people, infants,
or those taking other medicines). Risk can also arise during a product’s
manufacture, such as contamination or counterfeiting. The effectiveness or
safety of products can be affected by improper handling
and transportation,
inappropriate supply, or administration or use by unqualified people. A guiding
principle for regulating therapeutic
products is that the likely benefits should
outweigh the likely risks and their regulation should be proportionate to those
benefits
and risks.
- Other
guiding principles important in helping achieve the Bill’s aim are that
regulation of therapeutic products should support
timely access to products,
open and well-functioning markets, and innovation. Regulation should also
support choice of, and equity
of access to, therapeutic products. There should
be co-operation with overseas regulators and, if appropriate, alignment with
international
standards and practice.
- The
Bill’s aim and guiding principles mean therapeutic products will be
regulated across their life cycle with obligations being
imposed on people
involved in a product’s supply chain.
- The
regulatory scheme consists of two broad components:
- market
authorisation requirements, which regulate which therapeutic products may be
imported into, supplied in, or exported from New
Zealand; and
- controlled
activity and supply chain activity requirements, which regulate how those
therapeutic products can be dealt with and by
whom.
- The
Bill also establishes a Therapeutic Products Regulator to administer the
regulatory scheme. The Regulator will be responsible
for ensuring the safety,
quality and efficacy or performance of regulated products across their life
cycle.
- The
Bill provides the Regulator with a range of compliance and enforcement powers
backed up by a comprehensive offence and civil penalty
regime.
Consistency of the Bill with the Bill of Rights Act
Section 14 – Freedom of expression
- Section
14 of the Bill of Rights Act affirms the right to freedom of expression,
including the freedom to seek, receive, and impart
information and opinions of
any kind in any form. The right to freedom of expression has also been
interpreted as including the right
not to be compelled to say certain things or
to provide certain information.2
- There
are a vast number of provisions in the Bill which prima facie engage the
right to freedom of expression. Some of these provisions are prescriptive,
describing in detail what is required and by
whom, while others set out more
generic requirements that may be drawn upon further in any regulations (noting
secondary legislation
is also subject to the Bill of Rights Act).
- These
provisions can be broadly split into the following categories:
- Requirement
to provide information: There are a number of clauses that require the
sponsor (that is, a holder of a market authorisation) of certain products to
notify
the Regulator of certain things. For example, clause 145 requires a
sponsor to notify the Regulator of likely shortages if they have
reasonable
grounds to believe that demand in New Zealand for a reportable product is likely
to exceed supply at any time in the next
6 months. Clause 206 states that an
inspector may, by written notice, require a specified person to give the
Regulator any information
that they reasonably need for regulatory purposes.
Clause 365 states that in assessing an application, the Regulator may obtain any
other information they consider appropriate from any source.
- Notification
of misconduct: There are a number of clauses that require people to notify
the Regulator if there are issues of misconduct. For example, clause 183
states
that if a responsible person for a licence has reason to believe that a relevant
person has contravened a provision of the
Bill or has attempted or intends to do
so (amongst other things) the responsible person must promptly notify the
licensee of their
belief and the reasons for it. Clause 189 requires a sponsor
or person in the supply chain to notify the Regulator of known or suspected
tampering or a risk of tampering.
2 See, for example, Slaight
Communications v Davidson 59 DLR (4th) 416; Wooley v Maynard [1977] USSC 59; 430 US
705 (1977).
- Labelling:
There are a number of clauses that require people to comply with certain
labelling requirements. For example, clause 187 prohibits
a person from
tampering with a therapeutic product, threatening to do so, or claiming to have
done so. The meaning of “tamper
with” includes to interfere with its
identification or labelling, its package, or its product information or consumer
information
in a way that adversely affects or might reasonably be expected to
affect the product in specified ways. Clause 326 allows the court
to make any
orders it thinks appropriate in relation to the defendant’s future use of
identification, labelling, packages,
or advertisements for therapeutic products
if the defendant has contravened provisions relating to these
matters.
- Advertising:
There are a number of clauses that require people to comply with certain
advertising requirements. For example, clause 194 prohibits
a person from
advertising a therapeutic product unless it has appropriate authorisation and
complies with the advertising and distribution
requirements. This includes that
the advertisement must include the name of the person using the advertisement to
promote the product
and if it is an advertisement for an NHP, it must not make a
health benefit claim that is not a permitted health benefit claim for
the NHP.
In addition, the Regulator may make an advertising remediation order (such as
directing the advertiser to distribute a correction)
if satisfied on reasonable
grounds that the advertiser has distributed, or caused the distribution of, an
advertisement for a therapeutic
product in contravention of clause 194 (see
clause 218).
- Impermissible
health benefit claims: Clause 192 prohibits the sponsor of an NHP with a
market authorisation from making a health benefit claim about the NHP unless it
is a permitted health benefit claim or is made in accordance with the rules
about how health benefit claims may be made.
- Prohibition
on asking for benefit: Clause 195 prohibits the sponsor or a supplier of a
therapeutic product from giving a benefit to a health practitioner or
veterinarian
with the intention of inducing them to make favourable clinical
decisions about the product. It also prohibits a health practitioner
or
veterinarian from accepting or asking for such a benefit.
- A
limit on a right may nonetheless be consistent with the Bill of Rights Act if
the limit is justified under s 5 of that Act. The
s 5 inquiry asks:
- does
the provision serve an objective sufficiently important to justify some
limitation of the right or freedom?
- if
so, then:
- is
the limit rationally connected with the
objective?
- does
the limit impair the right or freedom no more than is reasonably necessary for
sufficient achievement of the objective?
- is
the limit in due proportion to the importance of the
objective?3
20. We consider that any limits
on the freedom of expression contained within the Bill are justified under s 5
of the Bill of Rights
Act because:
3 Hansen v R [2007] NZSC 7, [2007] 3 NZLR
1.
- The
overall objective of the Bill, which is to provide for the comprehensive, risk-
proportionate regulation of therapeutic products
is sufficiently important to
justify some limit on s 14. The objective of many of these provisions is to
ensure compliance with the
regulatory regime. For example, they enable the
Regulator to assess an application for an NHP or require a sponsor or person in
the
supply chain to provide information to enable the Regulator to determine
whether the Bill is being complied with. The objective of
other provisions is to
support public health, such as by regulating advertising and the kinds of claims
that can be made about NHPs
and prohibiting health practitioners from asking
sponsors or suppliers of therapeutic products for benefits. Requiring parties to
provide information to the Regulator and prohibiting certain claims and requests
go to the heart of the regulatory regime and, as
such, we consider it reasonable
for persons to be required to comply with these requirements.
- The
requirements imposed on people to provide certain information in specific
circumstances are rationally connected to this objective.
Ensuring that relevant
information is provided in the prescribed manner to all necessary parties is
fundamental for achieving the
Bill’s regulatory and public health
objectives.
- The
requirements in the Bill limit freedom of expression no more than reasonably
necessary for the regime to operate efficiently and
are proportionate to the
importance of the Bill’s objectives. We note in particular that many of
these provisions involve factual
information and contain limited expressive
value, and that people will choose to be part of the regulatory regime in the
course of
business. Under clause 365, people who have not chosen to be part of
the regulatory regime may be requested by the Regulator to provide
information.
However, there is a public interest in there being a sufficient ability for the
Regulator to obtain relevant information.
- Accordingly,
any limits to s 14 are justified under s 5 of the Bill of Rights
Act.
Section 20 – Rights of minorities
- Section
20 of the Bill of Rights affirms that individuals who belong to an ethnic,
religious, or linguistic minority in New Zealand
shall not be denied the right,
in community with other members of that minority, to enjoy the culture, to
profess and practice the
religion, or to use the language, of their
minority.
- The
Bill appears to limit this freedom under the Bill of Rights Act by regulating
NHPs, which includes rongoā Māori and
Traditional Chinese Medicine, in
so far as it restricts an individual’s right to import, supply, export,
and provide information
about such NHPs in the course of
business.
Market authorisation and controlled activities
- Clause
67 prohibits a person from importing, supplying, or exporting an NHP in the
course of a business or undertaking, unless the
product has requisite
authorisation. “Business or undertaking” means a business,
professional practice, or other undertaking,
whether or not carried on for gain
or reward.4
4 See clause 14 of the Bill. We have been
informed that this Bill is not intended to regulate individuals’ personal
or domestic
affairs.
- Clauses
122 to 125 provide for the issue of market authorisations for NHPs. They differ
from the provisions relating to medicines
to reflect the fact that the risks
associated with NHPs are generally less than the risk associated with medicines.
For example,
there is no requirement to establish the efficacy of the product
(like the requirement for medicines).
- Clause
69 provides a person must not carry out a controlled activity unless they have a
licence, permit, or are allowed by a provision
of subpart 3 of Part 3.
Controlled activities in relation to NHPs means manufacturing or exporting an
NHP, or importing a low concentration
NHP, in the course of business. The
criteria for granting a licence (clause
158) or permit for
controlled activities (clause 165) include criteria relating to ensuring
adequate management of the risks with
carrying on the controlled activity.
- The
Bill contains carve outs for NHPs from the requirements regarding market
authorisation and controlled activities in some circumstances,
including the
following:
- Clause
111 provides an exception to the requirements of clause 69 as outlined above and
allows the sponsor of an NHP with market authorisation
to manufacture or export
it without needing a licence.
- Clause
112 provides an exception to the requirements in clause 67 and 69 outlined above
and allows an NHP practitioner to manufacture,
supply or export an NHP without
authorisation if they meet the specified
criteria.5
- Clause
67(2) provides an exception to the requirements in clause 67, as outlined above,
where the product is a low concentration
NHP.
Impermissible health benefit claims
- Clause
192 prohibits the sponsor of an NHP with a market authorisation from making a
health benefit claim about the NHP unless it
is a permitted health benefit claim
or is made in accordance with the rules about how health benefit claims may be
made. However,
clause 61 states that a health benefit claim about an NHP may be
substantiated by scientific evidence, evidence of traditional use,
or both. It
also states that information about the traditional use of a product or
ingredient that is in a pharmacopeia listed in
the regulations is prima facie
evidence of that use.
Discussion
- We
have considered if the limit on the right is consistent with the Bill of Rights
Act in accordance with the test at paragraph 19
above.
- On
balance, we are satisfied that some limitation on the right to s 20 of the Bill
of Rights Act is justifiable given the important
public health objectives of the
regulatory scheme. In coming to this view, we note that these provisions aim to
provide for the acceptable
safety and quality of NHPs across their life cycle,
and to adequately regulate health benefit claims made about NHPs. Regulating
the
import, supply, export, and provision of information about NHPs in the course of
business is rationally connected with these
5 Clause 112 allows an NHP practitioner to
manufacture and supply an NHP that does not have market authorisation if it is
manufactured
for a specific client after the practitioner has determined that it
is appropriate for the client and the other criteria in the clause
are met. If
the client is overseas, but ordinarily in New Zealand, the NHP practitioner can
export it to the client.
objectives. The limit is no greater than reasonably necessary and
proportionate to the objectives as the Bill only regulates those
who are acting
in the course of business or undertaking, and not those acting in a personal or
domestic capacity. In addition, there
are less stringent requirements for NHPs
than there are for medicines to reflect their lower risk as well as carve outs
of the regulatory
scheme for NHPs (as outlined above).
Section 21 – Unreasonable search and seizure
- Section
21 of the Bill of Rights Act affirms that everyone has the right to be secure
against unreasonable search or seizure, whether
of the person, property,
correspondence or otherwise. The right protects a number of values, including
personal property, dignity,
and privacy.6
- Ordinarily,
a provision found to limit a particular right or freedom may be consistent with
the Bill of Rights Act if it can be considered
reasonably justified in terms of
s 5 of that Act. However, the Supreme Court has held that an unreasonable search
logically cannot
be demonstrably justified and therefore the inquiry does not
need to be undertaken.7 Rather, s 21 is self-limiting
in that the assessment to be undertaken is whether the search power is
reasonable. The reasonableness
of a search and seizure can be assessed with
reference to the purpose of the search and seizure and the degree of intrusion
on the
values which the right seeks to protect.
Regulatory
powers
- Subpart
2 of Part 7 provides regulatory powers to enable the Regulator to perform their
surveillance, response and compliance monitoring
functions. The powers are
exercisable by appointed inspectors and the Regulator (who is, by definition,
also an inspector). Clause
355 also provides that the Regulator may exercise any
of their powers under this subpart to obtain information or things at the
request
of an overseas regulator.
- The
Bill provides the Regulator with a number of regulatory powers that engage s 21,
for example:
- The
requirement for a sponsor, licensee or permit holder, person in the supply
chain, or other person listed in the Bill to give the
Regulator any information
the Regulator reasonably needs for regulatory purposes (clause 206).
- The
power for an inspector to require the sponsor of a therapeutic product to take
samples and test products and devices, or give
the Regulator a sample or a
sample of a device’s output, for testing (clause 207).
- The
power to enter a place (clause 208) where a supply chain activity or an activity
that a licence or permit allows to be done, is
being carried out. Upon entry the
inspector may (see clause 210):
- inspect
or examine the place and anything found there that relates to a supply chain
activity, an activity related to a licence or
permit, or a therapeutic
product;
6 See, for example,
Hamed v R [2011] NZSC 101, [2012] 2 NZLR 305 at [161] per Blanchard
J.
7 Hansen v R [2007] NZSC 7, [2007] 3 NZLR 1
(SC) per Blanchard J.
- test
any equipment, process or procedure;
- take
samples;
- make
records or recordings of things done at the place;
- take
copies of documents or information produced; and
- use
any equipment they reasonably need.
35. Subpart 3 of Part 7 also
allows the Regulator to make a recall order for a therapeutic product if
satisfied that the continued
availability of the product poses a risk to health.
A recall order may also impose requirements on people in the supply chain to,
for example, return or dispose of the product. The Regulator may also seize or
require the destruction of a prohibited product or
product that has been
misrepresented as a therapeutic product (clause 224).
- The
Bill provides that a person who impedes the Regulator or an inspector in these
activities commits an offence and may be subject
to a fine on conviction.
- Overall,
we consider that the prima facie limits to the right under s 21 are
reasonable in the circumstances. In particular:
- A
person may only be required to obtain or compile information for the purposes of
giving it to the Regulator, where the inspector
is satisfied on reasonable
grounds that it is reasonable to require the person to do so. Personal
information is generally excluded
unless the information could not reasonably be
obtained without the personal information being disclosed.
- Persons
must be given a reasonable timeframe within which to comply with the notice to
provide information or samples or undertake
testing.
- The
power of the Regulator to either require a sponsor to take samples or provide
information is limited to persons described in the
Bill, all of whom voluntarily
participate in the regulatory regime knowing that they will be subject to
regulatory requirements.
- Any
sample taken or required to be tested must be no more than the smallest sample
reasonably needed for the purpose for which it
is required.
- Although
the degree of intrusiveness is high as the inspector may enter property that is
private, without providing any prior notice,
entry to a home, a marae or
associated building, or a consultation treatment room that is in use, may only
be made with consent of
the occupier or in accordance with a warrant issued
under the Search and Surveillance Act 2012.
- The
expectation of privacy in a public welfare regulatory context is lower than in
other contexts. The power of entry and inspection
may only be used in places
where a supply chain activity or an activity that a licence or permit allows to
be done, is being carried
out.
- On
entering a place, the inspector’s powers to inspect, examine, and test any
equipment, process or procedure is limited to
anything found there that relates
to a supply chain activity carried on at that place, an activity that a licence
or permit
allows to be carried on at the place, and
therapeutic products that are or were at the place.
- The
inspector is not permitted to access or require anyone to give them access to
any computer system, or data storage device that
is not part of a therapeutic
product.
- When
entering a place an inspector must take reasonable steps to find the person in
charge of the place, identify themselves and inform
them of the purpose of
entry.
- Section
60 of the Evidence Act 2006 applies to this subpart, which means a person can
refuse to provide information to the inspector
if the information would likely
incriminate the person for an offence.
- Recall
orders may only be made by the Regulator if they are satisfied, on reasonable
grounds, that the continued availability of the
product directly or indirectly
creates or increases a significant risk to personal or public
health.
- The
requirement to destroy or give the Regulator a prohibited product relates to a
product that exposes an individual to a risk of
death, serious injury or serious
illness and the risk cannot be adequately managed by the Regulator’s
powers.
- In
so far as the Bill allows these powers to be exercised at the request of an
overseas regulator (clause 355), they may be exercised
at the discretion of the
Regulator and only where the Regulator is satisfied that it is appropriate to do
so. The powers are also
rationally connected with the functions of the Regulator
which include engaging and cooperating with overseas regulators and
organisations,
which in turn facilitates the Regulator being able to rely on
reports, assessments, decisions or information received from overseas
regulators.
- We
have concluded that these regulatory powers contain sufficient safeguards to
ensure that they are reasonable under s 21 of the
Bill of Rights Act, taking
into account the public health rationale for which these powers are being
exercised and the safeguards
around the use of these
powers.
Investigative powers
- Subpart
1 of Part 8 sets out investigative powers to enable the Regulator to investigate
and obtain evidence of noncompliance with
the Bill and perform their
investigative functions. A number of these powers engage s 21 with associated
offences for non- compliance
under this subpart.
- For
example, clause 240 allows the Regulator to authorise an inspector to enter and
search a specific place if the Regulator reasonably
suspects that a provision of
the Bill has, is being, or will be, contravened and that the search will find
evidential material relating
to that contravention. The inspector may enter and
search the place with the consent of the occupier or under a search warrant. The
provisions of the Search and Surveillance Act 2012 relating to search,
surveillance, and inspection powers and production orders
apply to a search
under this part. On entering, the inspector has the same search powers for
enforcement purposes as they would for
regulatory purposes.
- The
Bill also allows an inspector who is exercising a regulatory power of entry, and
finds evidence of a contravention of the Bill,
to carry on exercising that
power. This means
that an inspector who has entered a place for
regulatory purposes and finds evidence of an offence does not have to leave the
place
and get a search warrant before continuing the search. They can remain at
the place and continue exercising that power for enforcement
purposes.
- Although
this permits a departure from the original purpose of the search, we consider
that this expansion is reasonable. To require
the inspector to leave the
premises and apply for a search warrant would enable evidence of non-compliance
to be removed or destroyed,
having the effect of undermining the Bill’s
objective to protect public health and the Regulator’s enforcement
powers.
- This
subpart also provides for the destruction of things seized under this subpart.
Given the safeguards in the Search and Surveillance
Act that apply to searches
under this subpart and the importance of removing products from circulation that
pose a risk to public
safety, we consider that these seizure powers are
reasonable.
- An
inspector who finds a person contravening the Bill, or reasonably suspects that
the person has done so, may require that person
to give their name and address.
It is an infringement offence to fail to provide this information. This
information is necessary
to be able to take any kind of enforcement action
against that person.
- Clause
327 also enables a court to make orders about forfeiture or disposal of
therapeutic products that are the subject of proceedings
and things related to
them. This also prima facie engages s 21. However, we consider this
seizure power is reasonable, as its purpose is to remove from circulation
certain products
(including ingredients or packaging) which may be harmful to
public health.
- Although
the intrusion on privacy is high, we consider that there are sufficient
safeguards to ensure that the intrusion is no greater
than necessary in order to
enable the Regulator to enforce the provisions of the Bill. The ability of the
Regulator to take enforcement
action is dependent on their ability to gather
evidence of any contravention. We therefore consider that the search powers are
necessary
and reasonable in these
circumstances.
Conclusion
- We
have concluded that in so far as the regulatory, investigative and enforcement
powers contained in the Bill constitute search and
seizure and engage s 21, they
are reasonable when viewed in light of the Bill’s objectives of protecting
public health and
safety, and the purpose of the Regulator’s powers to
monitor compliance with the regulatory regime and to enforce the provisions
of
the Bill.
Section 25(c) – Right to be presumed innocent until proven guilty
- Section
25(c) of the Bill of Rights Act affirms the right of everyone charged with an
offence to be presumed innocent until proven
guilty according to law. The right
to be presumed innocent requires the Crown to prove an accused person’s
guilt beyond reasonable
doubt.
- Strict
liability offences prima facie limit s 25(c) of the Bill of Rights Act.
This is because a strict liability offence may be proved by a finding that
certain facts
occurred without proof of mens rea. The accused is required
to prove a defence (on the balance of probabilities), or disprove a presumption,
to avoid liability. This
means that, where the accused is unable to prove a
defence, they could be convicted even where reasonable doubt about their guilt
exists.
- Strict
liability offences may nevertheless be justifiable limits on rights under s 5 of
the Bill of Rights Act. They have been found
to be more likely to be justifiable
where:
- The
offences are regulatory in nature and apply to persons participating in a highly
regulated industry;
- The
defendant will be in the best position to justify their apparent failure to
comply with the law, rather than requiring the Crown
to prove the opposite;
and
- The
penalty for the offence is proportionate to the importance of the Bill’s
objective.
- The
Bill contains numerous strict liability offences for contravention of provisions
under the Bill (refer subpart 3 of Part 8), which
give rise to a prima facie
issue of inconsistency with s 25(c).
- We
have concluded that the strict liability offences are justified for the
following reasons:
- The
offences serve the important objective of promoting compliance with the Bill in
order to protect public health.
- We
consider that the fines are reasonable, likely to be commensurate with the
entities’ or individuals’ ability to pay
and necessary to ensure
compliance with the Bill. The maximum penalty for a strict liability offence is
a fine of an amount set out
in the offence provision, but ranges from between
$30,000 and $100,000 for individuals, and otherwise between $170,000 and
$500,000.
- The
court maintains the discretion to impose a lesser
penalty.
- Because
there is no requirement to prove a state of mind, the fines are considerably
less than those for fault-based offences.
- Subpart
10 of Part 8 of the Bill provides a defence if the defendant took all reasonable
steps to ensure that the conduct constituting
the contravention did not occur
and to mitigate any effect the conduct had in creating or increasing a
significant risk to personal
health or public health. Common law defences of
absence of fault are also available to the defendant. The defendant will be best
placed to demonstrate that they took reasonable steps or there was a total
absence of fault.
- Clauses
318 and 319 include certain presumptions regarding labels and samples relating
to any proceedings under the Bill, unless the
contrary is proved. This places
the burden of proof on the defendant to prove otherwise. We consider that the
presumption with respect
to samples is reasonably justified as it would be
impractical to require the Regulator to test every product from an identified
quantity
of therapeutic products. With respect to labelling, it is reasonable to
presume that the package conforms with that description and
that the person
identified on the label carried out a supply chain activity. In both cases, in
any proceedings under the Bill the
defendant is best placed to be able to show
that the presumption is incorrect.
- The
Bill also contains a number of infringement offences resulting in the
requirement to pay an infringement fee or fine. The quantum
is to be set out in
regulations but will be at the lower end of the penalty scale. The Bill provides
that an infringement fee must
not be more than 5% of the strict liability
penalty (or if there is no strict liability offence,
$1,000) and a
fine must not be more than the strict liability penalty (or if there is no
strict liability offence, $5,000). A person
issued with an infringement offence
may either pay the infringement fee or elect for the matter to go to court, and
the matter will
generally dealt with in accordance with the Criminal Procedure
Act for a category 1 offence. However, if they are found to have committed
the
contravention, that is not a conviction.
- The
context for these strict liability and infringement offences is within a highly
regulated environment designed to protect public
health. They apply to
individuals engaged within that regulated environment and in contexts where
defendants have an opportunity
to provide a defence. Fines are also set at a
level that accounts for no-fault-based offences. Bearing all these factors in
mind,
these offences appear to be justifiable limits to the right to be presumed
innocent.
Section 26(2) – Double jeopardy
- For
completeness, we have considered whether the offence provisions engage the right
in s 26(2) of the Bill of Rights Act to be protected
from double jeopardy. While
subpart 6 of Part 8 of the Bill expressly prevents a person who contravenes a
provision of the Bill being
subject to both a civil penalty order and liability
for an offence, the Bill does not specifically address the situation where a
person’s conduct constitutes 2 or more offences (whether knowledge based,
strict liability or infringement offences).
- We
consider that the Bill can be read consistently with the Bill of Rights Act in
this respect, because the criminal rule of double
jeopardy would apply to ensure
that a person cannot be held criminally liable twice for the same conduct.
Therefore, although the
Bill gives the Regulator a range of options for
enforcing compliance with the Bill, only one of those options can be used with
respect
to the same conduct. Section 26(2) of the Act is therefore not
engaged.
Conclusion
- We
have concluded that the Bill appears to be consistent with the rights and
freedoms affirmed in the Bill of Rights Act.
Edrick Child
Acting Chief Legal Counsel Office of Legal Counsel
NZLII:
Copyright Policy
|
Disclaimers
|
Privacy Policy
|
Feedback
URL: http://www.nzlii.org/nz/other/NZBORARp/2022/71.html